Key Research Sites In Germany Join Verified Clinical Trials Research Subject Registry To Prevent Duplicate Subjects & Over Enrollment To Improve Safety & Data Quality

Share Article

Several premier research centers in Germany have led the initiative and joined the global Verified Clinical Trials (VCT) research subject database registry to prevent duplicate subjects and other important protocol violations in an effort to improve safety and data quality in their clinical trials.

Key research sites in Germany join Verified Clinical Trials to prevent duplicate subjects and over enrollment globally to improve research subjects safety & data quality

For some time now we have been looking for an innovative system that prevents clinical trial participants from enrolling more than once in clinical trials at multiple study centres. We are delighted that we have found the Verified Clinical Trials platform..

Several premier research centers in Germany have led the initiative and joined the global Verified Clinical Trials (VCT) research subject database registry to prevent duplicate subjects and other important protocol violations in an effort to improve safety and data quality in their clinical trials. KFGN, CTC North, Nuvisan, and Boehringer Ingelheim’s phase 1 unit have begun use of the VCT system and joined a network of other sites across Europe with VCT to combat a global dilemma phase 1 units and clinical trials research sites experience. These organizations face the challenge of detecting and preventing duplicate enrollment and professional research subjects joining multiple research studies in parallel or simultaneously. Without the use of a tool like VCT preventing over-enrollment in clinical trials is nearly impossible. Similar to other regions across the research world, Germany has multiple research sites in close proximity and issues with research participants visiting multiple research sites contemporaneously. Verified Clinical Trials offers a GDPR compliant de-identified registry as a tool to help prevent over enrollment and duplicate subjects at the time of screening. The protections continue for the entire duration of the study. Verified Clinical Trials does help detect and prevent other key protocol violations for patient studies as well.

Mitchell Efros M.D. FACS, CEO of VCT stated, “These special companies have made an important decision and taken an important step to protect the quality and safety of their clinical trials by joining the research subject database registry Verified Clinical Trials. This issue cannot be tackled alone, and by joining forces CTC North, Nuvisan, KFGN, and Boehringer Ingelheim are doing all they can to make clinical trials research as safe as possible and are uniting the research community. We are expecting more research sites and CROs to join the battle against over-enrollment.”

Kerri Weingard, ANP, COO of VCT added, “Verified Clinical Trials data reveals that research subjects are willing to travel long distances for access to study related healthcare and stipends. Our experience has shown us that all phases of clinical trials research as well as most therapeutic indications have significant issues with the phenomenon of duplicate subjects and over-enrollment. No country or region is seemingly immune to this reality. Without a tool like the VCT research subject database registry, there would be no way to detect or prevent these issues. We applaud these companies for working with VCT and placing safety and data quality as the priority”

Martin Manzoni, Head of Technical Support in the Human Pharmacology Center of Boehringer Ingelheim, “For some time now we have been looking for an innovative system that prevents clinical trial participants from enrolling more than once in clinical trials at multiple study centres. We are delighted that we have found the Verified Clinical Trials platform, which is being used in Germany as well as in neighbouring countries such as Belgium and the Netherlands. Before its implementation, we made especially sure that the data is stored within the EU and that it adheres to all aspects of data protection according to the EU GDPR (EU DSGVO). We would very much welcome using Verified Clinical Trials throughout Germany as well as expanding it to other EU countries.”

Ralf Freese, Medical Director at CTC North says: “After being in the business for over 20 years it seems that the clinical science community in Germany and hopefully Europe has finally found a trustworthy system to protect the safety of study participants and the integrity of data on a whole new level. This is an important step for CROs, Sponsors and especially our patients.”

“For emovis, patient safety is most important in all clinical trials that we conduct”, says Dr. Bettina Bergtholdt, CEO of emovis GmbH. “Our goal is to provide patients with innovative treatment options for their health issues and meanwhile keeping them safe. Joining the Verified Clinical Trials Database will definitely help us achieve those goals.”

About Verified Clinical Trials (VCT)

Verified Clinical Trials is the largest global research subject database registry to prevent duplicate subjects and over enrollment from phase 1 – phase 4 clinical trials. VCT spans across multiple countries and multiple therapeutic indications to promote safety and improved data quality. With support of hybrid fingerprint biometric and identity based technology, VCT has created a global HIPAA and GDPR compliant system that has been adopted across a great number of phase 1 units as well as multi-site phase 2-4 CRO and sponsors managed clinical trials.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mitchell D. Efros
@VerifiedTrials
Follow >
Visit website